The FDA has granted 510(k) clearance to Microstructure Imaging's MICSI-PET, a software platform that uses structural MRI data to enhance neurological PET images and automatically quantify amyloid and tau biomarkers. By applying MRI-guided denoising and super-resolution processing, the platform sharpens PET image quality while preserving the underlying signal — a meaningful upgrade for reading borderline or equivocal scans.

The platform automatically generates Centiloid values for amyloid PET and CenTauR values for tau PET, along with regional SUVr scores and z-scores benchmarked against normative data. It is compatible with amyloid, tau, and FDG PET studies across multiple scanner vendors and generations.

Key Takeaways

• Amyloid and tau PET have become central to Alzheimer's care since the approvals of lecanemab and donanemab, both of which require biomarker confirmation before treatment
• The Centiloid and CenTauR scales standardize measurements across different tracers and scanners, reducing variability in reads
• MICSI is also pursuing a $2.275M NIH Phase II grant for multicenter validation of a future neuroimaging platform with NYU Langone and Memorial Sloan Kettering

Why it matters: As antiamyloid therapies enter clinical practice, accurate and reproducible PET quantification directly shapes treatment decisions. Tools like MICSI-PET that automate and standardize these reads could help clinicians act with greater confidence, especially in ambiguous cases.